ValiRxOpportunity Contact
Mark Treharne, Head of Corporate Development
London, United Kingdom

ValiRx Website
TherapeuticPreclinical Pharmalicensing.com

BC201 is a combination of the peptide ingredient of VAL201 (a decapeptide currently in clinical testing for Oncology) with complementary active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19.

Introduction/Background
BC201 is a combination therapy for the treatment of patients with Coronavirus in development by a consortium of Valirx, Oncolytika and Black Cat Bio.

  • Combination of:
    • A SRC kinase-Androgen receptor interaction (SAI) inhibitor – VAL201 a decapeptide in clinical trials for prostate cancer
    • Long acting Niacin – for example extended formulation available, NiaSpan
    • DNAse – for example Pulmozyme
  • For immune system modulation/treatment of cytokine storm as well as direct anti-infective – combined approach to treat Acute Respiratory Distress
  • Prior safety data for all three components makes it a low risk combination
  • US provisional patent filing 1st June 2020 by Black Cat Bio Limited to cover the combination treatment

https://www.valirx.com/wp-content/uploads/2020/07/BlackCat-COVID-19-ARDS-treatment-summary.pdf

Description of Technology
The theoretical action of the peptide is two-fold, by blocking the Androgen Receptor mediated activity of SRC Kinase, the peptide is postulated to down-regulate the expression of TMPRSS2 a transmembrane protein believed to be required for Coronavirus cell entry; and by directly dampening the immune response.

Val201 – Src Kinase-Androgen Receptor Inhibition

  • Decapeptide mimetic in trials for hormone driven cancers
  • Efficient blocker of AR-Src Kinase SH3 domain association and autophosphorylation
  • Blocks Src activation, Src/Erk pathway activation, cyclin D1 expression and proliferation
  • Blocks (rapid) non-genomic signalling whilst maintaining genomic AR signalling
  • Less side effects than broad Src kinase inhibition

Inhibition of AR/Src association and downstream pathway activation is anticipated to block:

  • Viral cell binding – by reduced TMPRSS2 expression
  • Membrane associated protease primes SARS CoV 2 spike protein for ACE2 binding
  • Src promotes TMPRSS2 expression through AR mediated non-genomic signaling
  • Viral replication – viruses hijack cellular kinase machinery
  • Src inhibition blocks Dengue viral capsid protein and RNA production in-vitro
  • SH3 domain critical

NETosis – regulated by rapid kinase dependent transcription firing

  • Src, Erk1/2 and Akt as well as cyclin Dependent kinase (CDK4/6) implicated
  • Erk, Akt, cyclin are downstream of Src-AR activation, potential link NETosis to AR level

Advantages
Patent filed June 2020.

Type of Business Relationship Sought
Licensing or Investment

COGNIS GROUP MISSION
The pace of change in our world continues to accelerate.  We all see this play out on the grand stage daily:  new diseases, warming oceans, increased hurricanes and fires, supply shortages, changes in social behaviors, more focus on alternative energies; the list goes on and on.  
We all have a role in proactively preparing for the ongoing shifts that we will encounter.  Our passionate team at Cognis Group is focused on helping you navigate innovation potential for the greatest collective benefits to people, the planet, and long term profits.

For more information, contact us:
info@cognisgroup.com
US: +1 303 709 3157
UK: +44 1904 435190